Skip to main content

Advertisement

SpringerLink
Log in

Low Expression of IGFBP7 is Associated with Poor Outcome of Pancreatic Ductal Adenocarcinoma

  • Translational Research and Biomarkers
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Insulin-like growth factor binding protein 7(IGFBP7) has been implicated as a potential tumor suppressor in various human cancers, although the role of IGFBP7 in pancreatic ductal adenocarcinoma (PDAC) is still unknown. We investigated the expression pattern and clinical significance of IGFBP7 in human PDAC.

Methods

IGFBP7 expression was evaluated by immunohistochemistry in 190 patients with PDAC who underwent surgical tumor resection. Expression of IGFBP7 was correlated with that of p53 and Ki-67, clinicopathologic features. We also evaluated overall survival (OS) according to expression of IGFBP7 by Kaplan–Meier and Cox regression analyses.

Results

IGFBP7 expression was significantly downregulated in pancreatic cancer tissues compared with adjacent normal pancreas (P < 0.001) and was inversely associated with Ki-67 expression (r = −0.284, P < 0.001). No significant relationships were found for clinicopathologic features, such as diameter of tumor, node status, grade, and stage. Importantly, low expression of IGFBP7 was associated with poor OS, and this was also significant in multivariate Cox regression analysis (hazard ratio [HR], 1.38; 95 % confidence interval [95 % CI], 1.00–1.91; P = 0.05).

Conclusions

We demonstrate for the first time that IGFBP7 is downregulated in pancreatic cancer, and low expression of IGFBP7 is correlated with increased proliferation and poor postoperative survival. IGFBP7 may be a tumor suppressor in PDAC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  2. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer. 1995;76:1671–7.

    Article  PubMed  CAS  Google Scholar 

  3. Jamieson NB, Carter CR, McKay CJ, Oien KA. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res. 2011;17:3316–31.

    Article  PubMed  CAS  Google Scholar 

  4. Ben QW, Wang JC, Liu J, Zhu Y, Yuan F, Yao WY, et al. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2010;17:2213–21.

    Article  PubMed  Google Scholar 

  5. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, et al. 1423 Pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10:1199–-210; discussion 1210–1.

    Article  PubMed  Google Scholar 

  6. Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009;13:1337–44.

    Article  PubMed  Google Scholar 

  7. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.

    Article  PubMed  CAS  Google Scholar 

  8. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993;165:68–72; discussion 72–3.

    Article  PubMed  CAS  Google Scholar 

  9. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg. 1997;226:248–57; discussion 257–60.

    Article  PubMed  CAS  Google Scholar 

  10. Burger AM, Leyland-Jones B, Banerjee K, Spyropoulos DD, Seth AK. Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J Cancer. 2005;41:1515–27.

    Article  PubMed  CAS  Google Scholar 

  11. Wilson HM, Birnbaum RS, Poot M, Quinn LS, Swisshelm K. Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. Cell Growth Differ. 2002;13:205–13.

    PubMed  CAS  Google Scholar 

  12. Walker GE, Antoniono RJ, Ross HJ, Paisley TE, Oh Y. Neuroendocrine-like differentiation of non-small cell lung carcinoma cells: regulation by cAMP and the interaction of mac25/IGFBP-rP1 and 25.1. Oncogene. 2006;25:1943–54.

    Article  PubMed  CAS  Google Scholar 

  13. Sato Y, Chen Z, Miyazaki K. Strong suppression of tumor growth by insulin-like growth factor-binding protein-related protein 1/tumor-derived cell adhesion factor/mac25. Cancer Sci. 2007;98:1055–63.

    Article  PubMed  CAS  Google Scholar 

  14. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell. 2008;132:363–74.

    Article  PubMed  CAS  Google Scholar 

  15. Suzuki H, Igarashi S, Nojima M, Maruyama R, Yamamoto E, Kai M, et al. IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis. 2010;31:342–9.

    Article  PubMed  CAS  Google Scholar 

  16. Ruan W, Xu E, Xu F, Ma Y, Deng H, Huang Q, et al. IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis. Cancer Biol Ther. 2007;6:354–9.

    Article  PubMed  CAS  Google Scholar 

  17. Burger AM, Zhang X, Li H, Ostrowski JL, Beatty B, Venanzoni M, et al. Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. Oncogene. 1998;16:2459–67.

    Article  PubMed  CAS  Google Scholar 

  18. Landberg G, Ostlund H, Nielsen NH, Roos G, Emdin S, Burger AM, et al. Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors. Oncogene. 2001;20:3497–505.

    Article  PubMed  CAS  Google Scholar 

  19. Tomimaru Y, Eguchi H, Wada H, Kobayashi S, Marubashi S, Tanemura M, et al. IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma. Int J Cancer. 2011,2:319–27.

    Google Scholar 

  20. Gronborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, Sato N, et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics. 2006;5:157–71.

    PubMed  CAS  Google Scholar 

  21. Katz MH, Hwang R, Fleming JB, Evans DB. Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin. 2008;58:111–25.

    Article  PubMed  Google Scholar 

  22. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer. 2002;86:886–92.

    Article  PubMed  CAS  Google Scholar 

  23. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer. 2003;98:474–83.

    Article  PubMed  Google Scholar 

  24. Yamasawa K, Nio Y, Dong M, Yamaguchi K, Itakura M. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer. Clin Cancer Res. 2002;8:2563–9.

    PubMed  CAS  Google Scholar 

  25. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004;10:2846–50.

    Article  PubMed  CAS  Google Scholar 

  26. Oh Y, Nagalla SR, Yamanaka Y, Kim HS, Wilson E, Rosenfeld RG. Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II. J Biol Chem. 1996;271:30322–5.

    Article  PubMed  CAS  Google Scholar 

  27. Yamanaka Y, Wilson EM, Rosenfeld RG, Oh Y. Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J Biol Chem. 1997;272:30729–34.

    Article  PubMed  CAS  Google Scholar 

  28. Chen Y, Pacyna-Gengelbach M, Ye F, Knosel T, Lund P, Deutschmann N, et al. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activity in human lung cancer. J Pathol. 2007;211:431–8.

    Article  PubMed  CAS  Google Scholar 

  29. Ruan WJ, Lin J, Xu EP, Xu FY, Ma Y, Deng H, et al. IGFBP7 plays a potential tumor suppressor role against colorectal carcinogenesis with its expression associated with DNA hypomethylation of exon 1. J Zhejiang Univ Sci B. 2006;7:929–32.

    Article  PubMed  CAS  Google Scholar 

  30. Sprenger CC, Damon SE, Hwa V, Rosenfeld RG, Plymate SR. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer. Cancer Res. 1999;59:2370–5.

    PubMed  CAS  Google Scholar 

  31. Vizioli MG, Sensi M, Miranda C, Cleris L, Formelli F, Anania MC, et al. IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene. 2010;29:3835–44.

    Article  PubMed  CAS  Google Scholar 

  32. Amemiya Y, Yang W, Benatar T, Nofech-Mozes S, Yee A, Kahn H, Holloway C, Seth A. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors. Breast Cancer Res Treat. 2011;126:373–84.

    Article  PubMed  CAS  Google Scholar 

  33. Wajapeyee N, Kapoor V, Mahalingam M, Green MR. Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines. Mol Cancer Ther. 2009;8:3009–14.

    Article  PubMed  CAS  Google Scholar 

  34. Sprenger CC, Vail ME, Evans K, Simurdak J, Plymate SR. Over-expression of insulin-like growth factor binding protein-related protein-1(IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis. Oncogene. 2002;21:140–7.

    Article  PubMed  CAS  Google Scholar 

  35. Benatar T, Yang W, Amemiya Y, Evdokimova V, Kahn H, Holloway C, et al. IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways. Breast Cancer Res Treat. 2011 [Epub ahead of print].

  36. Seth A, Benatar T, Amemiya Y, Yang W, Holloway C, Nofech-Mozes S. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors. Hugo J. 2010;4:110–1.

    Google Scholar 

  37. Sun HC, Qiu ZJ, Liu J, Sun J, Jiang T, Huang KJ, et al. Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol. 2007;30:1359–67.

    PubMed  CAS  Google Scholar 

  38. Stanton KJ, Sidner RA, Miller GA, Cummings OW, Schmidt CM, Howard TJ, et al. Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. Am J Surg. 2003;186:486–92.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

Authors are grateful to Zhang Jing (Changhai Hospital), Xu Jingjing (Changhai Hospital), Wang Yang (Changhai Hospital), and Man Xiaohua (Changhai Hospital) for their skillful technical assistance. This study was supported by grant 81072025 from the National Natural Science Foundation of China.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Gastroenterology, Changhai Hospital of Second Military Medical University, Shanghai, China

    Wei An MD, Qi-wen Ben MD, Hai-tao Chen MD, Gui-xiang Li MD & Zhao-shen Li MD

  2. Center for Clinical Epidemiology and Evidence-based Medicine, Second Military Medical University, Shanghai, China

    Wei An MD, Qi-wen Ben MD, Hai-tao Chen MD & Zhao-shen Li MD

  3. Pathology, Changhai Hospital of Second Military Medical University, Shanghai, China

    Jian-ming Zheng MD & Ling Huang MD

Authors
  1. Wei An MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qi-wen Ben MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hai-tao Chen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jian-ming Zheng MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ling Huang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gui-xiang Li MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhao-shen Li MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhao-shen Li MD.

Additional information

An Wei and Ben Qiwen contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

An, W., Ben, Qw., Chen, Ht. et al. Low Expression of IGFBP7 is Associated with Poor Outcome of Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 19, 3971–3978 (2012). https://doi.org/10.1245/s10434-012-2407-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-012-2407-2

Keywords

Search

Navigation